Liposome-encapsulated dimethyl curcumin inhibits over-activation of rat lymphocyte to relieve collagen-induced arthritis by regulating intracellular proteolysis and PCNA/p21/caspase-3 pathway

2021-08-05 12:26:42YaMingGuoZhiYuanSunXiaoQiangSunXiaoyingZhou
Life Research 2021年3期

Ya-Ming Guo, Zhi-Yuan Sun, Xiao-Qiang Sun, Xiaoying Zhou

Liposome-encapsulated dimethyl curcumin inhibits over-activation of rat lymphocyte to relieve collagen-induced arthritis by regulating intracellular proteolysis and PCNA/p21/caspase-3 pathway

Ya-Ming Guo1#, Zhi-Yuan Sun1#, Xiao-Qiang Sun2, Xiaoying Zhou1, 3*

1Immunopharmacology Institute, School of Pharmacy, Changzhou University, Changzhou, Jiangsu, China.2School of Petrochemical Engineering, Changzhou University, Changzhou, Jiangsu, China.3The School of Medicine, the University of Southampton, Southampton SO16 6YD, UK.

Dimethyl curcumin, a synthetic derivative of curcumin, has good anti-cancer, anti-arthritis and anti-inflammatory properties, but underline mechanism was unclear. Activation, differentiation, proliferation and apoptosis of lymphocytes have important functions during arthritis development and immune homeostasis. Over-activation of lymphocyte causes inflammatory cytokines storm, leading to an immune imbalance and tissue damages. The aim of this study was to investigate the anti-inflammation mechanism of liposome encapsulated dimethyl curcumin (Lipo-DiMC) on over-activated rat spleen lymphocytes. In this study, Lipo-DiMC was produced to increase the solubility; the primary rat spleen lymphocytes were extracted and the Concanavalin A induced cell activation model was established to study the cellular responses to Lipo-DiMC treatment in-vitro. The results showed that Lipo-DiMC suppressed Concanavalin A-induced cell proliferation, inhibited cells entering G2/M phase, and reduced the ratio of necrosis/apoptosis by manipulating intracellular p53/p21/PCNA/JNK-1 pathways. Furthermore, Lipo-DiMC increased the accumulations of intracellular matrix metalloproteinase-9 and reduced matrix metalloproteinase-9 secretion of rat spleen lymphocytes. Also, Lipo-DiMC increased intracellular caspase-3 expression and reduced Cat-C activity in activated rat spleen lymphocytes, involving in intracellular proteolysis. Our findings suggest that dimethyl curcumin effectively alleviates Concanavalin A induced over-activation of rat spleen lymphocytes, thereby inhibiting inflammatory cytokines storm and restoring cell homeostasis.

Liposomes encapsulated dimethyl curcumin, Rheumatoid arthritis, Rat spleen lymphocytes, Intracellular proteolysis

Background

Dimethyl curcumin (DiMC, [1,7-bis(3,4-methoxyphenyl)-1,6-heptadiene-3,5-dione], Chemical Abstracts Service: 52328-98-0) is a synthetic analogue of curcumin and a bioactive polyphenol having good anti-inflammatory, anti-cancer and metabolic stability properties[1-3]. Liposome encapsulated dimethyl curcumin (Lipo-DiMC) is a new approach of delivery system for DiMC with better effects than DiMC by increase slow-release, bioavailability, biological stability[3-6].

Rheumatoid arthritis (RA) is a chronic, inflammatory disease of uncertain pathogenesis, and characterized by the over-activation, differentiation and proliferation of lymphocytes[7,8]. Patients with RA have dysregulated lymphocytes with over proliferation and differentiation; and activated peripheral blood lymphocytes have defects in apoptosis, correlating to the severity levels of RA[9,10]. Lymphocyte activation play an important role in RA and immune homeostasis[11]. During activation and proliferation, lymphocytes induce inflammatory cytokines storm which is a strong immune response to the pathogen invaders or autoantigens, causing various organ damages of the body.

Cell apoptosis (the programmed cell death) is essential for developmental biology and maintenance of the body homeostasis in continuously renewing tissues. Cell cycle is a multipronged process that directs cellular proliferation through a series of checkpoints that correct for DNA damage, genetic derangements and other errors, and regulated by numerous regulatory proteins, such as p21, p27, proliferating cell nuclear antigen (PCNA), p53 and c-Jun N-terminal kinase (JNK-1, also called stress-activated protein kinase) that belong to the mitogen-activated protein kinasesignaling pathways involving in cell death, cell survival, cellular growth and differentiation.

Matrix metalloproteinase-2/9 (MMP-2/9, 72 kDa, 92 kDa) participate in extracellular matrixdegradation and remodeling. Over-expressions of MMP-2/9 are involved in inflammatory diseases. Cathepsin C is a lysosomal cysteine protease derived from immune-granulocytes; and functions in activating serine proteases, such as inflammatory enzymes: mast cell chymase/tryptase, neutrophil elastase, cytotoxic T lymphocyte granzyme A/B[12,13]. Caspase-3 is a well-known downstream intracellular killing protease in cell apoptosis.

Our previous in-vivo study showed the anti-arthritis effects of Lipo-DiMC in collagen-induced-arthritis rats [17], but the underlying cellular mechanism was not clear. In present in-vitro study, the primary rat spleen lymphocytes were extracted, a Concanavalin A (Con-A) induced cell-activation model was established to simulate the activation state of lymphocytes in RA, and Lipo-DiMC was applied to investigate the possible cellular biological mechanisms of Lipo-DiMC on lymphocytes. The cell growth, apoptosis and cell cycle were examined; the intracellular enzymatic activities of MMP-2/9, cathepsin-C and caspase-3 were assayed, the intracellular signal protein expressions of p53, p21, p27, PCNA, JNK-1 and annexin-V, also mRNA expressions of tumor necrosis factor α and Beclin-1 of rat spleen lymphocytes were detected.

Experimental section

Preparations of Lipo-DiMC and empty liposomes

DiMC was purchased from Tauto, Biotech (Shanghai, China). Soybean phosphatidylcholineand cholesterol and absolute ethyl alcohol (analytical reagent) were purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Lipo-DiMC was prepared by thin-film method as previously described[14]. Briefly, soybean phosphatidylcholine/cholesterol/DiMC in 4:4:1 (w/w/w) were dissolved in absolute ethyl alcohol and evaporated to dryness under reduced pressure in a rotary evaporator. The dried lipid film was hydrated in phosphatebuffered saline (phosphate buffered saline, pH7.0) and agitating for 30 minutes at 55 °C. Then, the lipid suspension was extruded through 0.1 μm and 0.2 μm pore size polycarbonate membranes on a nitrogendriven Lipex™ lipid extruder (Northern Lipids, Burnaby, BC, Canada). Liposome size and zeta potential were measured by Zetasizer NanoZS90 (Malvern, Malvern Hills, Worcestershire, UK). The partial size of Lipo-DiMC less than 0.2 μm was reached 97%[4].

Animal welfare

Six-week Sprague Dawley rats (male, 250–300 g) were purchased from Changzhou Cavens Lab Animal Company (Changzhou, Jiangsu, China). The Animals were treated in accordance with(8thedition, National Academies Press). All procedures were undertaken with the approval of the Changzhou University Ethics Association (application approval number: CCZU20191022).

Extraction of primary rat spleen lymphocytes and Con-A induced cell activation model

Spleen lymphocytes were extracted as previously described[6]. Briefly, the spleens were removed from Sprague Dawley rats and put in the tube containing phosphate buffered saline (PBS) with 4% penicillin-streptomycin (Hyclone, Logan City, Utah, USA). Under sterile condition, spleens were squeezed and mashed using 200 mesh cell strainers (Sigma-Aldrich, Shanghai, China). The red blood cells were lysed with Tris-NH4Cl red blood lysis buffer (Beyotime, Shanghai, China). The cells were washed with PBS and cultured in RPMI-1640 medium (Sigma) containing 10% fetal bovine serum (FBS, GIBCO-Thermofisher, Shanghai, China), 100 U/mL penicillin and 100 μg/mL streptomycin overnight to remove adherent cells. The lymphocytes in culture suspension were counted by trypan blue staining. Con-A induced cell lymphocyte activation model is a wide used cell model for lymphocyte activation study as previously described[15,16].

Cell viability assay

Spleen lymphocytes (5×105/well) were plated in 96-well plate and stimulated with or without Con-A (5 μg/mL; Sigma-Aldrich, Shanghai, China) for one hour; then incubated with DiMC (3, 6, 12 μg/mL), Lipo-DiMC (3, 6, 12 μg/mL) or empty liposomes (the amount was calculated in parallel to Lipo-DiMC treatments) for 24 hours in serum free condition, then the cells were incubated with additional Thiazolyl Blue Tetrazolium Bromide (0.5 mg/mL,Sigma-Aldrich, Shanghai, China) for 4 hours. Dimethyl sulfoxide was added to dissolve the formazan crystals and the optical densities (OD) were measured at 570 nm by Bio-Rad micro-plate reader. The cell grow rate was expressed in percentage (%) relative to untreated cells. The inhibitory rate was calculated by (ODuntreatedgroup-ODtreatedgroup) /ODuntreatedgroup × 100%.

Flow cytometry for annexin-V-FITC assay and cell cycle analysis

Cell cycle distribution: the spleen lymphocytes (1×106cells/mL) were treated with or without Lipo-DiMC (6,12 μg/mL) for 24 hours cells were suspended and fixed with 70% ethanol at 4℃, and subsequently resuspended in PBS containing 0.1 mg/mL RNase A. AnnexinV-FITC/propidium iodide (PI) double staining kit was applied according to manufacture instruction (Abcam, Cambridge, UK). Flow cytometry analysis was performed (Becton Dickinson FACS AccuriTM C6-plus). The fluorescence was measured, FL1 (Ex 488/Em530 nm) for annexin V-FITC and Fluorescence 3 (Ex 488/Em585 nm) for propidium iodide. 2-dimentional scatter dot plot with four different cell fractions: necrotic cells, up-left (UL) (−, +); later apoptotic cells, up-right (UR) (+, +); early apoptosis, low-right (LR) (+, −); alive cells, low-left (LL) (−, −) were analyzed by ModFit LT 5.0 software.

Measurement of cell apoptosis: the spleen lymphocytes (1×106cells/mL) were treated with or without Lipo-DiMC (6, 12 μg/mL) for 16 hours and then washed with ice-cold PBS. The cells stained with annexin-V primary antibody (1:50) in binding buffer (10 mM hepesfreeacid, 700 mM NaCl, 2.5 M CaCl2, pH 7.4) for 40 minutes; then labeled with secondary antibody (Fluorescein isothiocyanate) (1:50) and PI for 30 minutes. Labeled cells were acquired on Becton Dickinson FACSCalibur flow cytometer and characterized using a Becton Dickinson Accuri C6 software into four groups: alive cells (LL, annexin-V-FITC negative and PI negative), early apoptotic cells (LR, annexin-V-FITC positive and PI negative), secondary apoptotic or necrotic cells (UR, annexin-V-FITC positive and PI positive) and dead cells (UL,annexin-V-FITC negative and PI positive).

The preparation of cell lysate and cell supernatants

In 24-well plate, 3×106/mL spleen lymphocytes were cultured in presence or absence of Lipo-DiMC for 24 hours, at 37 ℃, 5% CO2atmosphere. Cells were then centrifuged at 14,000rpm for 10 minutes and the pellets and supernatants were separated. The cell supernatants were collected; the cell pellets were washed with PBS and lysed in lysis buffer (20 mM sodium acetate, 1mM Ethylene Diamine Tetraacetic Acid, 1% (v/v) TritonX-100, pH 5.5, containing 1mM phenylmethylsulfonyl fluoride protease inhibitor) (Beyotime Biotechnology, Shanghai, China).

Enzymatic activity assays for MMP-2/9 and cathepsin-C

The activity of matrix metalloproteinase 2 (MMP-2)and matrix metalloproteinase9 (MMP-9) in cell supernatant and cell lysates were detected respectively by gelatin zymography analysis as previously described[17]. Gel images were recorded by video camera (Gel Doc XR+, Bio-Rad) and the bands were quantified by Image Lab software (version 7.0; Bio-Rad Laboratories, Incorporation). Cathepsin C activity in cell lysates was evaluated using its specific substrates Gly-Phe-AFC (GF-AFC, home synthesized)[18] or Gly-Phe-4MβNA (BACHEM, Bubendorf, Switzerland) as previously described[19]. The fluorescence intensity was examined at Ex400/Em492 nm by fluorescence spectrometer (Perkin Elmer, Waltham, Massachusetts, USA), and the maxim speed of kinetic reaction (Vmax) was calculated.

Western blot

The total protein of each cell lysate was measured by BCA protein assay kit (Sigma-Aldrich, Shanghai, China). Equal amounts of proteins (20 μg/lane) were loaded and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and then further transferred onto polyvinylidene difluoride membrane. The membranes were blocked with 5% Bovine albumin in PBS with Tween at room temperature for 4 hours, then incubated overnight at 4 °C with corresponding primary antibodies (p21, p27, p53, PCNA, JNK-1, caspase-3 1:500, or GAPDH 1:2,000) (Abcam,Cambridge,UK).Themembraneswerethen washedwithTBScontaining0.05%Tween-20,andincubatedwithHorseradishPeroxidaselabeled secondary antibody accordingly for one hour at room temperature.Afterwashingagain,chemiluminescence (Perkin Elmer, Waltham, Massachusetts, USA) reagent was applied and photographed by Bio-Rad Gel Doc/Chemi Doc Imaging System. The bands representing the levels of protein expression were quantified by Image J software.

Table 1 Synergy Brands Green Reverse Transcription-Polymerase Chain Reaction primers pairs used for the quantification of targeted mRNA

Forward primer sequence on upper line, reverse sequence on lower line.1Amplicon lengths in base pairs.GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TNF-α, tumor necrosis factor α.

Quantitative real-time reverse transcriptase polymerase chain reaction

Total RNA of spleen lymphocytes (2×106) was extracted and cDNA was synthesized using cDNA Synthesis SuperMix (Transgen Biotech, Beijing, China). Synergy Brands Green Reverse Transcription-Polymerase Chain Reaction was performed for glyceraldehyde-3-phosphate dehydrogenase, tumor necrosis factor α (TNF-α) and Beclin-1 mRNA expressions using QuantiNovaTM SYBR® Green Polymerase Chain Reaction Kit (QIAGEN, Dusseldorf, Germany) and StepOnePlusTMReal-Time PCR instrument (Applied Biosystems-Thermofisher, Shanghai, China). Gene expression was calculated with the2-ΔΔCTmethod and normalized to GAPDH. The Primers, and the size of amplification products of tested genes are listed in Table 1.

Statistics

Prism software version 7.0 software was employed for statistical analysis. The Mann-Whitney non-parametric test for unpaired variables was employed to compare differences between groups. The Person r test was used for the degree of association between variables. All the results were expressed as mean ± standard error of mean (SEM).-value of <0.05 was considered to be statistically significant. *<0.05;**<0.01;***<0.001;****<0.0001.

Results

Lipo-DiMC reduced necrosis and induced apoptosis of primary rat spleen lymphocytes

The comparison between DiMC, Lipo-DiMC and empty liposomes was first thing been done. Dimethyl sulfoxide was needed to resolve the difficulties in making DiMC solution, but the final concentration of dimethyl sulfoxide in DiMC solution was above 0.1%, causing the cell death compared with untreated cells and Lipo-DiMC in PBS treated cells (DiMC is not dissolved in PBS), therefore, Lipo-DiMC was used for this study, but not DiMC(data not shown).

Dimethyl sulfoxide>0.1% is considered to induce cell toxicity unfortunately[20]; and the empty liposomes did not show the significant interruptions (Figure 1A). The results demonstrated that the cell growth rate was inhibited by Lipo-DiMC in dose-dependent manners (Figure 1A), where the carrier (empty liposomes) did not affect. Con-A stimulation increased cell relative growth rate by 37.5±1.8% compared with non-Con-A stimulation. In Con-A stimulation group, cells treated with Lipo-DiMC (3, 6, 12 μg/mL) for 24 hours, the inhibition rates (%) relative to untreated cells were increased by 20.36±3.15, 30.18±1.89 and 44.73±1.31(%, means±SEM) respectively (Figure 1B). In non-ConA stimulation group, after 24 hours treatment with Lipo-DiMC (3, 6, 12 μg/mL), the inhibitory rates (%) relative to untreated cells were 12±6.38, 20.5±1.5 and 20.5±1.5 (%, means±SEM) respectively (Figure 1B). The Con-A induced lymphocyte over-activation cell model was established.

2-D scatter dot plot with four different cell fractions: up-left, UL (−,+, necrosis or some later apoptosis); up-right, UR (+,+, later apoptosis); low-right, LR (−,−, early apoptosis); low-left, LL (+, −, alive cells) by Flow Cytometry analysis, demonstrated the differentiations of rat spleen lymphocytes after 24 treatment with Lipo-DiMC (0, 6, 12 μg/mL) (Figure 2C), the ratios of necrotic cells (UL: 8.2%, 3.3%, 1.7%) were decreased; the ratios of later apoptotic cells (UR: 6.2%, 11.3%, 16.4 %) a2nd early apoptotic cells (LR: 10.9%, 42.9%, 65.1%) were increased; and the ratios of the living cells (LL: 74.6%, 42.5%, 16.8%) were reduced respectively. The representative gated dot plots from flow-cytometry analysis shown in Figure 1D–G indicate that Lipo-DiMC could reduce necrotic cell death (Figure 1D), induce both early (Figure 1E), laterapoptotic(Figure1F)andnecrotics(Figure1G) cell death dose-dependently in vitro.

Figure 1 Lipo-DiMC induce apoptosis of rat spleen lymphocyte in-vitro. Relative to untreated cells, Con-A stimulated or unstimulated rat spleen lymphocytes were treated with or without Lipo-DiMC for 24 hours, (A) the relative growth rates (%) in different conditions compared to untreated cells (100%) and (B) the inhibitory rates (%) of Lipo-DiMC (3, 6, 12 μg/mL) on cell growth. (C) 2-D scatter dot plot with four different cell fractions: up-left (−,+, necrosis cells); up-right (+,+, later apoptotic cells); low-right (+, −,early apoptosis); low-left (−,−, alive cells) by Flow Cytometry analysis, showing distribution of cells under Lipo-DiMC treatment conditions (0, 6, 12 μg/mL) after flow cytometry acquisition and (D,E,F,G) the percentages of living, early apoptosis, later apoptotic and necrotic cells under different treatment conditions (=3–6, mean± SEM %). Lipo-DiMC, liposome encapsulated dimethyl curcumin; Con-A, Concanavalin A; SEM, standard error of mean.

Lipo-DiMC blocked cell cycle progression and induced cell cycle arrest at G0 stage

Cell cycle histograms of Con-A stimulated rat spleen lymphocytes treated with Lipo-DiMC (0, 6, 12 μg/mL) for 24 hours were shown respectively (Figure2A–C). The cells treated with 6 μg/mL of Lipo-DiMC, the percentage of G0/G1 phase was reduced by 0.61%, S phase was increased by 6.04% and G2/M phase was reduced by 5.43%, respectively compared with untreated cells. The cells treated with 12 μg/mL of Lipo-DiMC, the percentage of G0/G1 phase was increased by 7.79%, S phase and G2/M phase were decreased by 1.15% and 6.64% respectively compared with untreated cells.

Another set of cell cycle analysis for the cells activated by Con-A and treated with Lipo-DiMC (12 μg/mL) for 24 hours (Figure 2D–E). The increased cell percentage of sub-G0 (53.5%) and the decreased cell percentages at G0/G1 (33.4%), S (4.11%) and G2/M (5.37%) phases of Lipo-DiMC treated lymphocytes were observed in comparison with the untreated cells at sub-G0 (32.5%), G0/G1(46.2%), S (6.98%) and G2/M (9.51%) phases respectively.

Lipo-DiMC regulated intracellular proteins expression and mRNA expression

Western blotting analysis demonstrated that compared with untreated cells, Lipo-DiMC (0, 6 and 12 μg/mL) dose-dependently enhanced the expressions of p53, p21, PCNA and caspase-3; whereas the levels of p27 and JNK-1were dropped in the cells treated with 12 μg/mL of Lipo-DiMC (Figure 3A). The mRNA expressions of Beclin-1 (<0.001) and TNF-α (<0.05) were markedly increased in the cells treated with 12 μg/mL of Lipo-DiMC compared with the untreated cells (Figure 3B and C).

Lipo-DiMC induced intracellular MMP-9 accumulation and inhibitedcathepsin-C activities

MMP-2 and MMP-9 activities in cell lysates (intracellular form: Figure 4A–C) and in culture supernatants (secreting form: Figure 4D–F) released from rat spleen lymphocytes were detected by gelatin zymography. The results showed that Lipo-DiMC blocked MMP-9 secretion, resulting in the increased accumulations of intracellular MMP-9 (Figure 4A), but did not affect MMP-2 secretions (Figure 4D) from cells. When cells were treated with Lipo-DiMC (0, 3, 6 and 12 μg/mL), the intracellular MMP-9 activities relative to untreated cells were increased by 6.04±3.46%, 97.08±4.98% and 75.96±1.85% (means ± SEM) respectively (Figure 4B). The secretion from of MMP-9 was inhibited 12.59±1.64% and 12.78±1.03% respectively (Figure 4E). Lipo-DiMC (3, 6 and 12 μg/mL) reduced intracellular MMP-2 level relative to the untreated cells by 49.61±9.29% and 28.93±16.41% (Figure 4C); the MMP-2 secretion form in the supernatants were increased by 21.02±4.4%, 9.63±2.59% and 4.75±3.49% respectively (Figure 4F). The alterations of cathepsin-C activities in the cells with or without Con-A stimulation and with or without Lipo-DiMC (3, 6 and 12 μg/mL) treatments were observed (Figure 4G and H); Con-A stimulation increased intracellular cathepsin-C activities and Lipo-DiMC inhibited the cathepsin-C activities induced by Con-A. The concentrations of Lipo-DiMC at 3, 6, 12 μg/mL incubated with Con-A stimulated-cells for 24 hours would inhibit intracellular cathepsin-C activities by 44.85%, 34.34% and 41.70% respectively; the cells without Con-A stimulation, the inhibitory rates of Lipo-DiMC (3, 6 and 12 μg/mL) on intracellular cathepsin-C activities were 7.84%, 0.37% and 41.73% reactively, relative to untreated cells.

Discussion

ConA-induced lymphocyte activation cell model used in this study, is a commonly used cell model for lymphocyte’s over-activation study. The results from the present in-vitro study indicated that Lipo-DiMC may have a function in regulating intracellular proteolysis and signal pathways of activated rat spleen lymphocytes, leading to cell cycle-rest and cell apoptosis for the restoration of immune homeostasis.

The intracellular-matrix proteolysis is crucial for cell life. Caspase-3 is a classical killing executor, Lipo-DiMC increased intracellular level of caspase-3 in con-A stimulated rat spleen lymphocytes compared with untreated cells, indicating the apoptosis event occurred. MMP-9 was reported having an intracellular association with mitochondrial function and transportation from endoplasmic reticulum to Golgi [21,22]. An array of MMP-9 substrates from the intracellular matrixhas been found[23, 24]. The present data from zymograpgy analysis illustrated that Lipo-DiMC accumulated intracellular MMP-9 of lymphocytes, suggesting that Lipo-DiMC might involve in the post-translational modifications of MMP-9 and promote MMP-9 intracellular proteolytic function. Furthermore, our data showed that the intracellular cathepsin-C activities were markedly down-regulated by Lipo-DiMC, showing the blockages of downstream inflammatory enzymes activations. Lipo-DiMC intracellularly increased MMP-9 activity and decreased cathepsin-C activity, which accompanied with the increased expressions of caspase-3 and annexin-V, suggesting an intracellular proteolysis pathway in addition to the caspase-3 pathway in this setting, where Lipo-DiMC was influencing.

The data from 2-D scatter dot plot with four different cell fractions by flow cytometry analysis demonstrated that the percentages of necrotic cells of the Lipo-DiMC treated rat spleen lymphocytes were decreased and apoptotic cells were increased compared to the untreated cells, indicating that Lipo-DiMC treatment can reduce con-A-induced cell impropriate differentiations.

The activation and nuclear accumulation of p53 results in cell cycle arrest, mainly mediated by up-regulated expression of p21, while p53 activates PCNA expression and p21 inhibits PCNA in DNA replication activity, which co-effects on PCNA in DNA repair functions [25,26].

Figure 2 Effects of Lipo-DiMC on cell cycle of Con-A stimulated rat spleen lymphocytes (=3–6). Cell cycle histograms of: (A, B, C) Con-A spleen lymphocytes cultured with Lipo-DiMC (0, 6,12 μg/mL) for 24 hours; (D, E) Con-A stimulated lymphocytes with or without Lipo-DiCM (12 μg/mL) treatment for 24 hours. Lipo-DiMC, liposome encapsulated dimethyl curcumin; Con-A, Concanavalin A.

Figure 3 The effect of Lipo-DiMC on p53, p21, PCNA, p27, JNK-1 and caspase-3 protein expression detected by WB, and mRNA expressions of TNF-α, Beclin-1 in Con-A stimulated rat spleen lymphocytes. The Con-A stimulated rat spleen lymphocytes after treatment with Lipo-DiMC (0,6,12 μg/mL) for 24 hours: (A) intracellular p53, p21, PCNA, p27, JNK-1, caspase-3 and GAPDH protein expressions; the relative concentrations of mRNA calibrated with GAPDH of (B) Beclin-1 and (C) TNF-α (=3–6, mean ± SEM).*<0.05,***<0.001 represent significant differences compared to the untreated cells. Lipo-DiMC, liposome encapsulated dimethyl curcumin; Con-A, Concanavalin A; WB, westrn blot; PCNA, proliferating cell nuclear antigen; TNF-α, tumor necrosis factor α; JNK-1,c-Jun N-terminal kinases 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SEM, standard error of mean.

Figure 4 The different effects of Lipo-DiMC on MMP-2/9 and cathepsin-C activities in cell lysates and supernatants of rat spleen lymphocytes. The gelatin zymography images of MMP-2 (72kDa) and MMP-9 (92kDa): (A) in cell lysates and (D) in cell supernatants of Con-A stimulated cells treated with or without Lipo-DiMC. The integrated optical densities of the bands (B) intracellular MMP-9 and (C) intracellular MMP-2. (E) Released MMP-9 and (F) released MMP-2 by semi-quantitation analysis of the bands in gels (Image Lab software). (G) The intracellular cathepsin-C activities of Lipo-DiMC (0,3,6,12 μg/mL) treated cells with or without Con-A pre-stimulation. (H) The intracellular cathepsin-C activities of Con-A stimulated cells treated with Lipo-DiMC (0,3,6,12 μg/mL) or cathepsin-C inhibitor GF-FNH2 respectively (=3, mean±SEM).Lipo-DiMC, liposome encapsulated dimethyl curcumin; MMP-2/9, matrix metalloproteinase 2/9; MMP-2, matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9; Con-A, Concanavalin A; SEM, standard error of mean.

Figure 5 The intracellular signal pathways of Con-A induced over-activated rat spleen lymphocytes responded to the Lipo-DiMC treatment. Lipo-DiMC is taken by cells through cell membrane lipid-exchange. Lipo-DiMC induces cell cycle arrest by down regulating JNK-1 and up-regulating PCNA, P21, P53 expressions. Lipo-DiMC increased the accumulations of intracellular MMP-9 and inhibited MMP-9 secretion; also increased caspase-3 expression, MMP-9 might co-work with caspase-3, as an intracellular bio-scissors, involving in proteolysis related apoptosis of Con-A induced over-activated lymphocytes. Lipo-DiMC, liposome encapsulated dimethyl curcumin; JNK-1, c-Jun N-terminal kinase; MMP-2, matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9; Con-A, Concanavalin A. PCNA, proliferating cell nuclear antigen.

All the observations of present study demonstrated that Lipo-DiMC treatment may affect these co-effects of p53, p21, p27 and PCNA in rat spleen lymphocytes, inducing cell arrest at sub-G0 stage or G0/G1 phase, and also stopped cell entering G2/M phase, implicating a complicity by different factors in the cells.

The JNK-1 are responsible for activation of p53, which is involved in cell apoptosis, cell cycle arrest and cell autophagy[27–29]. The present data from cell cycle analysis showed that after Lipo-DiMC treatment, DNA replication of rat spleen lymphocyte was inhibited, which associated with the activation of JNK-1 expression. The data also showed that Beclin-1 mRNA and tumor necrosis factor α mRNA expressions were up-regulated in rat spleen lymphocytes by Lipo-DiMC. For overall, the cell apoptosis pathway was turned on by Lipo-DiMC condition during cell differ entiations, indicating the anti-proliferation effect of Lipo-DiMC on over-activated rat spleen lymphocytes by inducing cell resting and cell apoptosis (Figure 5).

Conclusion

This in-vitro study suggests a new pharmacological and cellular biological mechanism for Lipo-DiMC’s anti-inflammation and anti-arthritis functions. Lipo-DiMC restores immune homeostasis and recovers rat spleen lymphocytes from improper stimulations by regulating intracellular proteolysis involved in MMP-9 and cathepsin-C activities and the PCNA/p21/JNK-1 signal pathway of over-activated rat spleen lymphocytes.

1. Patwardhan RS, Checker R, Sharma D, et al. Dimethoxycurcumin, a metabolically stable analogue of curcumin, exhibits anti-inflammatory activities in murine and human lymphocytes.. 2011;82(6):642-657. Available: 10.1016/j.bcp.2011.06.024; https://dx. doi.org/10.1016/j.bcp.2011.06.024

2. Constantin T, Konstantinos D, Sofianos ZD, et al. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin.. 2007;13(4):1269-1277. Available: 10.1158/1078-0432.CCR-06-1839; https://dx.doi. org/10.1158/1078-0432.CCR-06-1839

3. Amit K, Atanu B, Sandur SK, et al. Differential antioxidant/pro-oxidant activity of dimethoxycurcumin, a synthetic analogue of curcumin.. 2011;45(8):959-965. Available: 10.3109/10715762.2011.571681; https: //dx.doi.org/10.3109/10715762.2011.571681

4. Zheng-yi L, Dan-di S, De-feng X, et al. Studies on preparation and properties of dimethyl curcumin liposome.. 2018;38(11):138-114. Available: 10.16606/j.cnki.issn 0253-4320.2018.11.028; https://doi.org/10. 16606/j.cnki.issn0253-4320.2018.11.028

5. Yoon MJ, Kang YJ, Lee JA, et al. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin.. 2014;5(3):e1112. Available: 10.1038/cddis.2014.85; https://dx. doi.org/10.1038/cddis.2014.85

6. Jayakumar S, Patwardhan RS, Pal D, et al. Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: possible involvement of ROS and thioredoxin reductase.. 2016;478(1):446-454. Available: 10.1016/j.bbrc.2016.06.144; https://dx. doi.org/10.1016/j.bbrc.2016.06.144

7. Ponchel F, Brown AK, Field SL, et al. Improvement of T-cell function in rheumatoid arthritis (RA) patients in clinical remission is associated with the recovery of IL-7 expression and depends on a familial history of RA.. 2005;7(1 Supplement):S1-S59. Available: 10.1186/ar1538; https://doi.org/ 10.1186/ar1538

8. Kugyelka R, Prenek L, Olasz K, et al. ZAP-70 regulates autoimmune arthritis via alterations in T cell activation and apoptosis.. 2019;8(5):504. Available: 10.3390/cells8050504; https://dx. doi.org/10.3390/cells8050504

9. Ponchel F, Morgan AW, Bingham SJ, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis.. 2002;100(13):4550. Available: 10.1182/BLOOD-2002-03-0671; https: //dx.doi.org/10.1182/BLOOD-2002-03-0671

10. Moro-García MA, Mayo JC, Sainz RM, Alonso-Arias R. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes.. 2018;9:339. Available: 10.3389/fimmu.2018.00339; https://doi.org/ 10.3389/fimmu.2018.00339

11. Datta S, Sarvetnick N. Lymphocyte proliferation in immune-mediated diseases.. 2009;30(9):430-438.Available: 10.1016/j.it. 2009. 06.002; https://doi.org/10.1016/j.it.2009.06. 002

12. Ruffell B, Affara NI, Cottone L, et al. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.. 2013;27(19):2086-2098. Available: 10.1101/gad.224899.113; https: //dx. doi.org/10.1101/gad.224899.113

13. Adkison AM, Raptis SZ, Kelley DG, et al. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis.. 2002;109(3):363-371. Available: 10.1172/JCI13462; https://doi.org/10.1172/ JCI13462

14. Dai F, Zhang X, Shen W, Chen J, Liu L, Gao G. Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors.. 2015;8:2601-2611. Available: 10.2147/OTT.S87931; https://dx. doi.org/10.2147/ OTT.S87931

15. Sun C, Jiang M, Zhang L, et al. Cycloastragenol mediates activation and proliferation suppression in concanavalin A-induced mouse lymphocyte pan-activation model.2017;39(3):131-139. Available: 10.1080/08923973. 2017.1300170; https://doi.org/10.1080/089239 73.2017.1300170

16. Chung CL, Leung KW, Lu WJ, et al. .Hinokitiol negatively regulates immune responses through cell cycle arrest in concanavalin A-activated lymphocytes.. 2015;2015:595824. Available: 10.1155/ 2015/595824; https://doi.org/10.1155/2015/59 5824

17. Toth M, Sohail A, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography.. 2012;878:121-135. Available: 10.1007/978-1-61779-854-2_ 8; https://doi.org/10.1007/978-1-61779-854-2_8

18. Liu X, Wang J, Chu Y, et al. Serum based fluorescent assay for evaluating dipeptidyl peptidase I activity in collagen induced arthritis rat model.. 2017;32:5-12. Available: 10.1016/j.mcp.2016.10.009; https://dx. doi.org/10.1016/j.mcp.2016.10.009

19. Chu Y, Guo Y, Walls AF, et al. The regulatory role of Dipeptidyl peptidase I on the activation of immune granulocytes.. 2017;41(10):1093-1102. Available: 10.1002/cbin.10815; https: //dx.doi.org/10.1002/cbin.10815

20. Creus N, Mateu J, Massó J, et al. Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote.. 2002;24(5):175-176. Available: 10.1023/A:10205 28203296; https://doi.org/10.1023/A:1020528 203296

21. Ali MA, Chow AK, Kandasamy AD, et al. Mechanisms of cytosolic targeting of matrix metalloproteinase-2.. 2012;227(10):3397-3404. Available: 10.1002/jcp.24040; https: //dx.doi.org/10.1002/jcp.24040

22. Eguchi T, Kubota S, Kawata K, et al. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene.. 2008;28(7):2391-2413. Available: 10.1128/MCB.01288-07; https://dx. doi.org/10.1128/MCB.01288-07

23. Cauwe B, Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases.. 2010;45(5):351. Available: 10.3109/10409238. 2010.501783; https://doi.org/10.3109/1040923 8.2010.501783

24. Cauwe B, Martens E, Proost P, et al. Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B/MMP-9 substrates.. 2009;1(5-6):404-426. Available: 10.1039/b904701 h; https://doi.org/10.1039/b904701h

25. Mikule K, Delaval B, Kaldis P, A, et al. Loss of centrosome integrity induces p38-p53-p21dependent G1-S arrest.. 2007;9(2):160-170. Available: 10.1038/ncb1529; https://dx. doi.org/10.1038/ncb1529

26. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network.. 2000;408(6810):307-310. Available: 10.1038/35042675; https://doi.org/ 10.1038/35042675

27. Oleinik NV, Krupenko NI, Krupenko SA. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene. 2007;26(51):7222-7230. Available: 10.1038/sj. onc.1210526; https://doi.org/10.1038/sj.onc.12 10526

28. Milne DM, Campbell LE, Campbell DG, et al. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1.. 1995;270(10):5511-5518. Available: 10.1074/jbc.270.10.5511; https://doi.org/10.10 74/jbc.270.10.5511

29. Patel R, Bartosch B, Blank JL. p21WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression.. 1998;111(Pt 15):2247–2255.

thanks Shuanglin Qin and other anonymous reviewers for the contribution to the peer review of this paper.

:

Correspondent author, Prof. Xiaoying Zhou has made contributions to the funding, organizations, conception, design, interpretation of data, drafted/edited and corrected the paper work critically for intellectual content; co-first author, Ya-Ming Guo and Zhi-Yuan Sun have made contributions to the funding, experimental works, technique operation, involved in animal model and cell model, data analysis, preparing the first draft and figures and corrections; Prof. Xiao-Qiang Sun has made contributions to experimental works, technique operation, data analysis, draft corrections.

:

DiMC, dmethyl curcumin; Lipo-DiMC, liposome encapsulated dimethyl curcumin; RA, rheumatoid arthritis; JNK-1, c-Jun N-terminal kinase; MMP-2/9, matrix metalloproteinase 2/9; MMP-2, matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9; Con-A, Concanavalin A; PBS, phosphate buffered saline; TNF-α, tumor necrosis factor α; OD, optical densities; UL, up-left; UR, up-right; LR, low-right; LL, low-left; PI, propidium iodide; SEM,standard error of mean ; PCNA,proliferating cell nuclear antigen.

:

The authors declare that they have no conflict of interest.

:

This work is supported by the Start-up Research Laboratory for Over-sea Talent Fund, China (No. Z391405) to Prof. Xiaoying Zhou and the Changzhou University Undergraduate Innovation and Entrepreneurship Fund, China (No. 2019-02-C-96) to Ya-Ming Guo.

:

Guo YM, Sun ZY, Sun XQ, Zhou X. Liposome-encapsulated dimethyl curcumin inhibits over-activation of rat lymphocyte to relieve collagen-induced arthritis by regulating intracellular proteolysis and PCNA/p21/caspase-3 pathway.. 2021;4(3):21. doi: 10.53388/life2021-0603-105.

:Shan-Shan Lin.

:03June 2021,

03 July 2021,

:10 July 2021

© 2021 By Authors. Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license (http://creativecommons.org/licenses/BY/4.0/

#Ya-Ming Guo and Zhi-Yuan Sun are the co-first authors of this paper.

*Corresponding to: Xiaoying Zhou. Immunopharmacology Institute, School of Pharmacy, Changzhou University,Hutang Town, Wujin District, Changzhou 213164, Jiangsu, China. E-mail: xiaoyingzhou@cczu.edu.cn. ORCID ID: 0000-0002-6756-5917.


登录APP查看全文